GRCE
Price
$3.13
Change
+$0.11 (+3.64%)
Updated
Jul 3 closing price
Capitalization
43.28M
IMUC
Price
$0.07
Change
-$0.03 (-30.00%)
Updated
Jul 2 closing price
Capitalization
8.99M
Interact to see
Advertisement

GRCE vs IMUC

Header iconGRCE vs IMUC Comparison
Open Charts GRCE vs IMUCBanner chart's image
Grace Therapeutics
Price$3.13
Change+$0.11 (+3.64%)
Volume$28.63K
Capitalization43.28M
EOM Pharmaceutical Holdings
Price$0.07
Change-$0.03 (-30.00%)
Volume$515
Capitalization8.99M
GRCE vs IMUC Comparison Chart in %
Loading...
GRCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMUC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRCE vs. IMUC commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRCE is a Hold and IMUC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (GRCE: $3.13 vs. IMUC: $0.07)
Brand notoriety: GRCE and IMUC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GRCE: 73% vs. IMUC: 13%
Market capitalization -- GRCE: $43.28M vs. IMUC: $8.99M
GRCE [@Biotechnology] is valued at $43.28M. IMUC’s [@Biotechnology] market capitalization is $8.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRCE’s FA Score shows that 0 FA rating(s) are green whileIMUC’s FA Score has 1 green FA rating(s).

  • GRCE’s FA Score: 0 green, 5 red.
  • IMUC’s FA Score: 1 green, 4 red.
According to our system of comparison, GRCE is a better buy in the long-term than IMUC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRCE’s TA Score shows that 5 TA indicator(s) are bullish while IMUC’s TA Score has 1 bullish TA indicator(s).

  • GRCE’s TA Score: 5 bullish, 3 bearish.
  • IMUC’s TA Score: 1 bullish, 5 bearish.
According to our system of comparison, GRCE is a better buy in the short-term than IMUC.

Price Growth

GRCE (@Biotechnology) experienced а +6.46% price change this week, while IMUC (@Biotechnology) price change was -30.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

GRCE is expected to report earnings on Jun 23, 2025.

IMUC is expected to report earnings on Nov 20, 2024.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GRCE($43.3M) has a higher market cap than IMUC($8.99M). GRCE YTD gains are higher at: -16.310 vs. IMUC (-57.879). IMUC has higher annual earnings (EBITDA): -5.65M vs. GRCE (-16.72M). GRCE has more cash in the bank: 11.1M vs. IMUC (85.3K). GRCE (0) and IMUC (0) have equivalent revenues.
GRCEIMUCGRCE / IMUC
Capitalization43.3M8.99M481%
EBITDA-16.72M-5.65M296%
Gain YTD-16.310-57.87928%
P/E RatioN/A0.02-
Revenue00-
Total Cash11.1M85.3K13,013%
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
GRCE vs IMUC: Fundamental Ratings
GRCE
IMUC
OUTLOOK RATING
1..100
6156
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
10
Undervalued
PROFIT vs RISK RATING
1..100
46100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
4996
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMUC's Valuation (10) in the Biotechnology industry is somewhat better than the same rating for GRCE (52) in the Pharmaceuticals Other industry. This means that IMUC’s stock grew somewhat faster than GRCE’s over the last 12 months.

GRCE's Profit vs Risk Rating (46) in the Pharmaceuticals Other industry is somewhat better than the same rating for IMUC (100) in the Biotechnology industry. This means that GRCE’s stock grew somewhat faster than IMUC’s over the last 12 months.

GRCE's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as IMUC (100) in the Biotechnology industry. This means that GRCE’s stock grew similarly to IMUC’s over the last 12 months.

GRCE's Price Growth Rating (49) in the Pharmaceuticals Other industry is somewhat better than the same rating for IMUC (96) in the Biotechnology industry. This means that GRCE’s stock grew somewhat faster than IMUC’s over the last 12 months.

GRCE's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as IMUC (100) in the Biotechnology industry. This means that GRCE’s stock grew similarly to IMUC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRCEIMUC
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GRCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMUC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UONEK0.680.04
+6.95%
Urban One
CBNK35.530.83
+2.39%
Capital Bancorp
TPB73.871.23
+1.69%
Turning Point Brands
BLCO13.880.12
+0.87%
Bausch + Lomb Corp
NKE76.39N/A
N/A
Nike

GRCE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRCE has been loosely correlated with IMVT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GRCE jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRCE
1D Price
Change %
GRCE100%
+3.64%
IMVT - GRCE
38%
Loosely correlated
+0.83%
SLNO - GRCE
38%
Loosely correlated
+0.51%
CYTK - GRCE
36%
Loosely correlated
+0.87%
SCNI - GRCE
31%
Poorly correlated
-2.95%
ATAI - GRCE
30%
Poorly correlated
+0.73%
More

IMUC and

Correlation & Price change

A.I.dvisor tells us that IMUC and GRCE have been poorly correlated (+7% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMUC and GRCE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUC
1D Price
Change %
IMUC100%
N/A
GRCE - IMUC
7%
Poorly correlated
+3.64%
TNXP - IMUC
6%
Poorly correlated
+0.88%
SRPT - IMUC
5%
Poorly correlated
+0.25%
ORMP - IMUC
5%
Poorly correlated
+0.93%
PTCT - IMUC
4%
Poorly correlated
-0.16%
More